Residual effects of intranasal methamphetamine on sleep, mood, and performance.
Although intranasal methamphetamine abuse has increased, there are no published data investigating the residual effects of the drug under controlled conditions. Thus, the current study examined the residual effects of single-dose intranasal methamphetamine administration on a broad range of behavioral and physiological measures. Non-treatment seeking methamphetamine abusers (n=11) completed this two-week, in patient, within-participant, double-blind study. The study consisted of four two-day blocks of sessions; each block was separated by at least 48 h. At approximately 10:00 h, on the first day of each block, participants received one of four intranasal methamphetamine doses (0, 12, 25, 50mg/70 kg). Lights were turned out at 23:00 h that evening and sleep measures were assessed. On the morning of the second day of each block, methamphetamine plasma levels, cardiovascular measures, mood, subjective reports of the previous evening's sleep, and psychomotor performance were assessed to determine residual drug effects. The larger methamphetamine doses (25 and 50 mg) markedly disrupted subjective measures of that night's sleep and some indices of next-day mood, but only the largest dose (50 mg) dose decreased objective measures of that night's sleep and increased next-day physiological measures. Methamphetamine did not produce any negative residual effects on early next-day performance. Future studies should assess methamphetamine-related residual effects following repeated doses administered over consecutive days.
Perez
Audrey Y
AY
Division on Substance Abuse, New York State Psychiatric Institute and Department of Psychiatry, College of Physicians and Surgeons of Columbia University, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA.
Kirkpatrick
Matthew G
MG
Gunderson
Erik W
EW
Marrone
Gina
G
Silver
Rae
R
Foltin
Richard W
RW
Hart
Carl L
CL
D000281:Administration, Intranasal; D018663:Adrenergic Agents / Q000008:administration & dosage* / Q000494:pharmacology*; D000328:Adult; D000339:Affect / Q000187:drug effects*; D003071:Cognition / Q000187:drug effects*; D039721:Diagnostic and Statistical Manual of Mental Disorders; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008694:Methamphetamine / Q000008:administration & dosage* / Q000494:pharmacology*; D008875:Middle Aged; D011597:Psychomotor Performance / Q000187:drug effects*; D012890:Sleep / Q000187:drug effects*; D011795:Surveys and Questionnaires
D018663:Adrenergic Agents; D008694:Methamphetamine